

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代碼: 02607)

NOTIFICATION LETTER 涌知信函

1 March 2024

Dear Shareholder,

Shanghai Pharmaceuticals Holding Co., Ltd.* (the "Company")

- Notice of Publication of Circular, Notice, Proxy Form and Reply Slip of Extraordinary General Meeting ("Current Corporate Communication")

The English and Chinese versions of the Current Corporate Communication are available on and may be accessed under "Announcements & Circulars" in the Investor Relations section of the Company's website at www.sphchina.com and are also available on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the Company is required to disseminate corporate communications ("Corporate Communications#") electronically. You may access the English and Chinese versions of the Company's Corporate Communications on the Company's website at www.sphchina.com and the HKEXNews website at www.shkcnews.hk.

If you wish to receive notifications from the Company on the availability of Corporate Communications on the Company's website in the future, you may provide a valid email address to us. The Company will send a notification to the provided email address each time when Corporate Communications are made available on the Company's website. Please complete the Provision of Email Address Form on the reverse side and submit it to the Company's H Share Registrar, Link Market Services (Hong Kong) Pty Limited ("Link"), at Suite 1601, 16/F, Central Tower, 28 Queen's Road Central, Hong Kong.

It is the responsibility of the shareholder to provide an email address that is functional. If the Company does not receive a functional email address from you, you will be unable to receive any notification regarding the publication of Corporate Communications. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications# to the email address provided by you without receiving any "non-delivery message".

We encourage you to access Corporate Communications of the Company in electronic form on the Company's website. If you wish to receive printed copies of Corporate Communications, you may refer to the relevant procedures stated on the Company's website at www.sphchina.com. The Company will promptly upon your request send the requested Corporate Communications to you free of charge.

Should you have any queries relating to any of the above matters, please call Link's telephone hotline at (852) 3707 2600 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday, excluding public holidays or send an email to hkenquiries@linkmarketservices.com.

By order of the Board Shanghai Pharmaceuticals Holding Co., Ltd.* ZHONG Tao Joint Company Secretary

* For identification purpose only

Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and accounts contained in them), notices of meetings, listing documents, circulars, proxy forms and reply slips. Actionable Corporate Communications refer to any corporate communications that seek instructions from the shareholders of the Company on how they wish to exercise their rights or make elections as the Company's shareholders.

各位股東:

上海醫藥集團股份有限公司 (「公司」)

- 臨時股東大會之通函、通告、代表委任表格及回條(「本次公司通訊」)之發佈通知

本次公司通訊之中、英文版本已上載於公司網站(<u>www.sphchina.com</u>)之投資者關係內的「公告與通函」網頁及香港聯合交易所有限公司披露易網站(<u>www.hkexnews.hk</u>),歡迎查閱。

根據香港聯合交易所有限公司證券上市規則(「上市規則」)第 2.07 條,本公司須透過電子方式發送公司通訊。 閣下可於本公司網站 <u>www.sphchina.com</u> 及香港交易所披露易網站 <u>www.hkexnews.hk</u> 瀏覽本公司的中、英文版本公司通訊。

如 閣下日後希望收到本公司的公司通訊已上載於本公司網站的通知,可以提供 閣下的有效電郵地址。每次本公司於本公司網站上載公司通訊時,本公司將發送通知至 閣下提供的電郵地址。請填妥在本函背面的電郵地址提供表格,然後交回至本公司的 H 股證券登記處,Link Market Services (Hong Kong) Pty Limited (「Link」),地址為香港皇后大道中 28 號中滙大廈 16 樓 1601 室。

股東有責任提供有效的電郵地址。如本公司沒有收到 閣下的有效電郵地址, 閣下將無法收到任何有關發佈公司通訊的通知。當本公司向 閣下提供 的電郵地址發送可供採取行動的公司通訊"時而沒有收到任何「未送達」的訊息,公司將被視為已遵守上市規則。

我們鼓勵 閣下於公司網站以電子形式瀏覽本公司的公司通訊。如 閣下希望收取本公司的公司通訊印刷本,可以參考本公司網站 <u>www.sphchina.com</u> 註明的相關程序。本公司將盡快免費向 閣下寄上所要求的公司通訊的印刷本。

如 閣下對本函內容有任何疑問,請致電 Link 電話熱線(852) 3707 2600,辦公時間為星期一至五(公眾假期除外)上午9時正至下午6時正,或電郵至 hkenquiries@linkmarketservices.com。

> 承董事會命 上海醫藥集團股份有限公司 聯席公司秘書

二零二四年三月一日

^{*} 僅供識別

[#]公司通訊乃公司向其證券持有人發出以供參照或採取行動的任何文件,包括但不限於年度和中期財務報告及其摘要報告(及其中包含的所有報告及帳目)、會議通告、上市文件、通函、 代表委任表格及回條。可供採取行動的公司通訊是指任何涉及要求本公司的股東指示其擬如何行使其有關股東權利的公司通訊。



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代碼: 02607)

PROVISION OF EMAIL ADDRESS FORM 電郵地址提供表格

致 To: 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.*

c/o Link Market Services (Hong Kong) Pty Limited

香港中環皇后大道中28號中滙大廈16樓1601室

Suite 1601, 16/F, Central Tower, 28 Queen's Road Central, Hong Kong

服務熱線 Services Hotline: (852) 3707 2600

電郵地址 Email: hkenquiries@linkmarketservices.com

(請用正楷英文填寫 Please complete in ENGLISH CAPITAL LETTERS)

證券持有人姓名 Name(s) of Securities Holder(s)	_	 																				 			
登記地址 Registered Address	_	 																				 			
聯絡電話號碼 Contact Telephone Number		 																				 			
電郵地址 Email Address	L	 <u></u>	1	1	1	1	1		1	1	1	<u> </u>	1	1	1	1	1	1	<u> </u>		 1	 	1	 1	
簽名 Signature		 															_	日其	月 D	ate		 			

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料整明

- PERSONAL INFORMATION COLLECTION STATEMENT **収集個人資料要明**In this statement, "Personal Data" has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 本党明中所指的「個人資料」具有香港法例第 486 章 (個人資料 (尾邊 條例) ("**《私邊條例**)) 中「個人資料」的演義。

 Your supply of Personal Data to the Company is on a voluntary basis, Your Personal Data may be used by the Company or be transferred to its Hong Kong Share Registrar for processing your instructions and/or request stated in this form and will be retained for such period as may be necessary for our verification and record purposes.

 関下是自願向本公司提供個人資料。関下的個人資料可被本公司用於或被轉移給本公司的香港證券登記處作為處理 関下在本表格上所述的指示及或要求,並將在邁當期間保留被等個人資料作核實及紀錄用途。

 You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing and addressed to the Personal Data Privacy Officer of Link Market Services (Hong Kong) Pty Limited 4 Stulie 1601, 1676, Central Tower, 28 Queen's Road Central, Hong Kong or by email at hkenquiries@linkmarketservices.com.

 周下有權程練 化隐條例)的條文查閱及或修改 関下的個人資料。任何該等查閱及或修改個人資料的要求均須以書面方式向 Link Market Services (Hong Kong) Pty Limited (地址為香港中環島后大道中 28 號中滙大厦 16 樓 1601 室)的個人意材配子作可需要解析。由于可能的工作,可能可能的工作,可能可能的工作,可能的工作,可能的工作,可能的工作,可能的工作,可能够可能的工作,可能的工作,可能的工作,可能可能的工作,可能可能的工作,可能的工作,可能的工作,可能可能的工作,可能可能的工作,可能可能的工作,可能可能的工作, 室)的個人資料私隱主任或電郵至 hkenquiries@linkmarketservices.com 提出